Calls Sold on Celldex Therapeutics (CLDX)
Shares of Celldex Therapeutics Inc. (NASDAQ: CLDX) are markedly lower on the session by 16.77%, currently trading $5.46. The stock is sinking after the company provided color on their current breast cancer study.
Calls are being largely sold on the name today. The June $7.50 call was just sold over 4,500 times on the offer; open interest on the strike is 7,643 contracts, indicating that a long call position was likely closed.
Call volume is running at 2.42x the daily average.
Celldex Therapeutics, Inc. is a biopharmaceutical company, which applies its Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases.
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.